Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study — Piero Barbanti (2023) | RDL Network
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
Article 2023 en
Authors
PB
Piero Barbanti
GE
Gabriella Egeo
CA
Cinzia Aurilia
Abstract
1 min read
Fremanezumab is characterized by an early and sustained efficacy in HFEM and CM patients with multiple preventive treatment failures in real-life, revealing an optimal safety and tolerability profile.
Discussion(0)
No comments yet. Be the first to comment.